A rice-based edible vaccine expressing multiple T-cell epitopes to induce oral tolerance and inhibit allergy.
Plant pollens are the most common cause of seasonal allergic disease. The number of patients undergoing treatment for allergies to the pollen of Japanese cedar (major antigens, Cry j 1 and Cry j 2) has increased steadily each year. A rice seed-based edible vaccine has been shown to be effective for treating Japanese cedar pollinosis. Rice seeds containing the major T-cell epitopes derived from cedar pollen allergens were orally administrated to mice before systemic challenge with total pollen protein. Mucosal immune tolerance leading to a reduction of allergen-specific IgE, T-cell proliferative reactions, and histamine were induced, resulting in suppression of allergy-specific symptoms such as sneezing. Oral seed-based peptide immunotherapy offers a safe, simple, and cost-effective alternative to conventional allergen-specific immunotherapy using crude allergen extracts for treating allergic disease. A human version of rice seed-based edible vaccine containing seven T-cell epitopes from the Cry j 1 and Cry j 2 allergens was recently developed and is undergoing safety assessments.
Takaiwa
Fumio
F
Transgenic Crop Research and Development Center, National Institute of Agrobiological Sciences, Kannondai 2-1-2, Tsukuba, Ibaraki 305-8602, Japan. takaiwa@nias.affrc.go.jp
D000284:Administration, Oral; D000818:Animals; D004195:Disease Models, Animal; D018984:Epitopes, T-Lymphocyte / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D012275:Oryza / Q000235:genetics / Q000276:immunology*; D030821:Plants, Genetically Modified / Q000235:genetics / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods*; D022462:Vaccines, Edible / Q000276:immunology
D018984:Epitopes, T-Lymphocyte; D022462:Vaccines, Edible